Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
Public ClinicalTrials.gov record NCT03137264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is being done to determine if non-invasive testing (urine and plasma testing) is as effective as tissue testing in identifying epidermal growth factor receptor (EGFR) T790M mutation status. EGFR is a type of protein found on the surface of cells in the body. When this protein is mutated and becomes too active, it can lead to cancer growth. T790M is a mutation that develops in response to treatment of the EGFR mutation. Participating patients will have tumor tissue (via cobas test), as well as 2 plasma samples (via cobas and Guardant360 tests) and 1 urine sample (via Trovera test), tested for EGFR T790M mutation status. If the results of the cobas tissue and/or plasma test show that a patient is T790M positive, they will be treated according to standard of care, which may include treatment with osimertinib. Osimertinib is approved for use in the United States for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT03137264
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2017 (Actual)
- Primary completion
- Nov 10, 2018 (Actual)
- Completion
- Nov 10, 2018 (Actual)
- Last update posted
- Nov 7, 2019
2017 – 2018
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Los Angeles | California | 90017 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | St. Helena | California | 94574 | — |
| Research Site | Deerfield Beach | Florida | 33442 | — |
| Research Site | Fort Lauderdale | Florida | 33308 | — |
| Research Site | Honolulu | Hawaii | 96819 | — |
| Research Site | Boise | Idaho | 83706 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Harvey | Illinois | 60426 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Southfield | Michigan | 48075 | — |
| Research Site | Brick | New Jersey | 08724 | — |
| Research Site | Farmington | New Mexico | 87401 | — |
| Research Site | White Plains | New York | 10601 | — |
| Research Site | Asheville | North Carolina | 28801 | — |
| Research Site | Hendersonville | North Carolina | 28792 | — |
| Research Site | Kettering | Ohio | 45409 | — |
| Research Site | Seattle | Washington | 98101 | — |
| Research Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03137264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2019 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03137264 live on ClinicalTrials.gov.